65247-27-0
Chemical Structure
Arvenin I
- CAS No.: 65247-27-0
- Formula:C38H56O13
- Molecular Weight:720.84
IUPAC Name: (R,E)-6-hydroxy-6-((2S,8S,9R,10R,13R,14S,16R,17R)-16-hydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-methyl-5-oxohept-3-en-2-yl acetate
InChIKey: PQOVWWZVVIGRPP-BBANTJNRSA-N
SMILES: CC(OC(C)(/C=C/C([C@@]([C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC([C@]3(C)[C@H]2CC=C4[C@H]3C[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)C(C4(C)C)=O)=O)(O)C)=O)C)=O
Biological Activity: Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway[1]. Arvenin I exhibits broad-spectrum antiproliferative against cancer cells[2]. Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice[1]. Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Arvenin I | 89.41% | Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway. Arvenin I exhibits broad-spectrum antiproliferative against cancer cells. Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice. Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Takemoto M, et al. Covalent Plant Natural Product that Potentiates Antitumor Immunity. J Am Chem Soc. 2025 Jan 22;147(3):2902-2912. [Content Brief]
- [2]. Minh CV, et al. Chemical constituents of Trichosanthes kirilowii and their cytotoxic activities. Arch Pharm Res. 2015 Aug;38(8):1443-8. [Content Brief]
